Glycogen storage disease type I surgery

Jump to navigation Jump to search

Glycogen storage disease type I Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glycogen storage disease type I from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glycogen storage disease type I surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glycogen storage disease type I surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glycogen storage disease type I surgery

CDC on Glycogen storage disease type I surgery

Glycogen storage disease type I surgery in the news

Blogs on Glycogen storage disease type I surgery

Directions to Hospitals Treating Glycogen storage disease type I

Risk calculators and risk factors for Glycogen storage disease type I surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Liver transplantation is the final treatment for patients with metabolic disease associated associated with GSD type 1.

Indications

Indications for liver transplantation include:[1]

  • Patients with multifocal
  • Growing lesions that do not regress with improved dietary regimens
  • Patients who do not have evidence of distant metastatic disease.

Surgery

  • Liver transplantation may improve the survival of patients with glycogen storage disease type 1.
  • Survival rates of patients after liver transplantation are:[2]
    • 1 year survival rate of 82%
    • 5 year survival rate of 76%
    • 10 year survival rate of 64%
  • There is resolution of metabolic derangements (correction of hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia) after liver transplantation in patients with GSD type 1.[3]

References

  1. Kishnani, Priya S.; Austin, Stephanie L.; Abdenur, Jose E.; Arn, Pamela; Bali, Deeksha S.; Boney, Anne; Chung, Wendy K.; Dagli, Aditi I.; Dale, David; Koeberl, Dwight; Somers, Michael J.; Burns Wechsler, Stephanie; Weinstein, David A.; Wolfsdorf, Joseph I.; Watson, Michael S. (2014). "Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics". Genetics in Medicine. doi:10.1038/gim.2014.128. ISSN 1098-3600.
  2. Maheshwari A, Rankin R, Segev DL, Thuluvath PJ (2012). "Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature". Clin Transplant. 26 (3): 432–6. doi:10.1111/j.1399-0012.2011.01549.x. PMID 22066793.
  3. O'Leary JG, Lepe R, Davis GL (2008). "Indications for liver transplantation". Gastroenterology. 134 (6): 1764–76. doi:10.1053/j.gastro.2008.02.028. PMID 18471553.

Template:WH Template:WS